Third-Quarter 2024 Business Review

Marcy l’Étoile, France, October 30, 2024 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2024.

+10.3% sales organic growth in the first nine months of the year with sales reaching €2,871m. A strong momentum fueled by the four growth drivers of the GO•28 strategic plan, growing +12%, together with a strong contribution from BIOFIRE^®1 respiratory panels:

• BIOFIRE^® non-respiratory panels sales are up +18% with all panels contributing strongly;
• Continued expansion of the SPOTFIRE^®2 solution, reaching sales of €53m and a total installed base close to 2,100 instruments (+600 in Q3);
• Solid dynamic in microbiology, with sales increase of +9%, driven by a 13% growth in reagent sales thanks to volume uptake and prices increases;
• Industrial Applications sales are up +9%, with double digit growth in reagents sales in both food and pharma segments;
• BIOFIRE^® respiratory panels sales increased +14%, illustrating the competitiveness and the high medical value of the solution, and benefiting from a sustained respiratory epidemiology.

+11% organic sales growth in Q3 2024 at €969m.

Confirmation of the 2024 full year revised guidance with a slight update on the expected impact of the currency effect:

• Organic sales growth between +8% and +10% at constant exchange rates;
• Contributive operating income before non-recurring items (CEBIT) is expected to grow between +12% and +17% at constant exchange rate ;
• The currency effect is expected to have a negative impact in the range of around -€60m on the 2024 annual CEBIT versus around -€70m previously.

Pierre Boulud, Chief Executive Officer, said: “bioMérieux delivered a dynamic performance in Q3 2024 in line with the strong results of the first half. Thanks to the very strong engagement from the bioMérieux team members, we continue to see positive momentum toward our GO•28 strategic plan targets. The double-digit growth in microbiology, non-respiratory BIOFIRE^® panels and industrial applications quarterly sales, together with the deployment of our point-of-care solution SPOTFIRE^®, demonstrate that we have identified the right drivers to pursue the development of bioMérieux. This also shows our portfolio meets the current public health needs. These positive achievements make us very confident in achieving our 2024 full year targets, that were recently revised upward.”

 

1. In this communication, BIOFIRE^® refers to BIOFIRE^® FILMARRAY^® TORCH system and panels.

2. In this communiation, SPOTFIRE^® refers to BIOFIRE^® SPOTFIRE^® system and panels.